Trial Profile

A Multicenter, Randomized, Open-label, Crossover, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) and IgPro10 (Intravenous Immunoglobulin, Privigen) in Adults With Systemic Sclerosis (SSc)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Jun 2023 Results reporting safety and pharmacokinetics data presented at the 24th Annual Congress of the European League Against Rheumatism
02 Aug 2022 Status changed from active, no longer recruiting to completed.
13 Jun 2022 This trial has been completed in France (End Date: 17 May 2022), according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com